Greg Sawyer, PhD
273: Super-resolution high-speed video microscopy reveals rapid cytotoxicity and cooperative dynamics of folate receptor alpha CAR T cells against ovarian cancer

Peter Forsyth, MD
349: A transcriptomic analysis of a first in human phase I trial of intrathecal dendritic cells in patients with leptomeningeal disease show development of adaptive immune responses

Mihaela Druta, MD 
523: Median OS of 21.5 months among 44 patients with treatment-refractory leiomyosarcoma, liposarcoma, and undifferentiated pleomorphic sarcoma treated with mecbotamab vedotin, an AXL-targeting ADC.

David Nubaum, MD
1321: A phase I clinical trial of intravesical therapy with autologous tumor infiltrating lymphocytes (TIL) in BCG-exposed non-muscle invasive bladder c

Daniel Abate-Daga, PhD
369: Chimeric antigen receptor-engineered TIL (CAR-TIL) show potent tumor recognition and greater tumor infiltration than conventional CAR-T cells

Kenneth Tsai, MD, PhD
529: Exploratory analysis of a phase 2 multicenter study evaluating local immune activation in the tumor microenvironment 12 weeks post VP-315, an investigational therapy for basal cell carcinoma (BCC)

Ahmad Tarhini, MD, PhD
156: A novel polygenic risk score predicts immune checkpoint inhibitor-mediated dermatitis in a North American high-risk melanoma patient population

Mihaela Druta, MD
322: Single-cell RNA sequencing of afamitresgene autoleucel indicates mechanisms of persistence and anti-tumor activity

Fatema Khambati
332: Enrichment of tumor-specific neoantigen reactive tumor infiltrating lymphocytes (TIL) in bladder cancer

Marine Potez
378: Renal Cell Carcinoma TIL expansion in controlled hypoxia enhances function and Tissue-Resident Memory phenotype

Christopher Polera
696: Turning metabolic adaptations into immunotherapeutic opportunities: RAS inhibition reshapes the tumor immunopeptidome

Rana Falahat
704: Melanoma cell–intrinsic regulation of tertiary lymphoid structure formation by STING signaling

Kenneth Tsai, MD, PhD
878: Pathway-Synthetic Senescence as a Means to Augment Immunotherapy Response

Andrew Deonarine
1280: Lung Cancer Cells Sample Local and Systemic Sources for MHC-II Presentation

Kedar Kirtane, MD
Cellular Therapies for Solid Tumors, Cell Therapies beyond CAR T Cells